Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 282 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RELAPSING REMITTING MULTIPLE SCLEROSIS Clear all
Terminated Phase 2 Interventional

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
LY3541860, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 8:42 PM EDT
Not listed Not applicable Interventional

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

NCT00210301
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Provigil (modafinil)
Drug
Lead sponsor
Institute for Clinical Research
Other
Eligibility
20 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Oct 13, 2026, 8:42 PM EDT
Terminated No phase listed Observational

Adherence Trial With MS LifeLines ® Services

NCT01905527
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 4 Interventional

AVONEX® Combination Trial - "ACT"

NCT00112034
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Methotrexate, IV methylprednisolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2008 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

NCT01667796
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 13, 2026, 8:42 PM EDT
Active, not recruiting No phase listed Observational

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

NCT05605782
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 13, 2026, 8:42 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions
Remibrutinib (Open Label)
Drug
Lead sponsor
Moein Amin
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 13, 2026, 8:42 PM EDT
Active, not recruiting Not applicable Interventional

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

NCT04009005
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Interventions
Therapeutic diet and lifestyle
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Development of a Motivational Intervention to Improve Treatment Adherence in MS

NCT01925690
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Motivational Interviewing-Cognitive Behavioral Therapy, Brief Education
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Kansas City, Missouri • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 13, 2026, 8:42 PM EDT
Completed No phase listed Observational

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00206635
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
33 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 13, 2026, 8:42 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

NCT02833714
View directory record Official record
Conditions
RELAPSING REMITTING MULTIPLE SCLEROSIS
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 13, 2026, 8:42 PM EDT
Completed No phase listed Observational

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

NCT00461396
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon-1beta (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 13, 2026, 8:42 PM EDT
Not listed Phase 1 Interventional

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

NCT00411723
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Interventions
RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo
Drug
Lead sponsor
Artielle ImmunoTherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 13, 2026, 8:42 PM EDT
Not listed Early Phase 1 Interventional

The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis

NCT01453868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Non Impact Aerobics, Passive : lecture series
Other
Lead sponsor
Nelson Mandela Metropolitan University
Other
Eligibility
20 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gaylord, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00340834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
35
States / cities
Cullman, Alabama • Phoenix, Arizona • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 13, 2026, 8:42 PM EDT
Not listed Phase 2 Interventional

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

NCT00217295
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex and Topamax
Drug
Lead sponsor
Multiple Sclerosis Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 13, 2026, 8:42 PM EDT
Completed No phase listed Observational

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 13, 2026, 8:42 PM EDT
Terminated No phase listed Observational

Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

NCT05978531
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Monomethyl Fumarate
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 13, 2026, 8:42 PM EDT
Completed No phase listed Observational

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT05663853
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
Not listed
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 13, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

NCT00203021
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer acetate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 13, 2026, 8:42 PM EDT